Recidivas y segundos tumores en el cáncer de pulmón de larga supervivencia

Escuín, Julio Sánchez de Cos; López, D. Peiteado; Delgado, Isabel Utrabo; Domínguez, Rocío Gallego; González, M. Agustín Sojo; Valle, Manuel Hernández

doi:10.1016/j.arbres.2015.07.013

Cited by 11 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 The development of second primary lung tumors has been estimated to occur at a rate of 1%–2% per year for patients with NSCLC and 6% for SCLC after successful treatment, with the majority of cases occurring after 5 years. 24 , 25 This possibility cannot be excluded in our cases.…”

Section: Discussionmentioning

confidence: 77%

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Abdallah

Nagasaka

Abdulfatah

et al. 2018

LCTT

View full text Add to dashboard Cite

IntroductionHistologic transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a well-recognized mechanism of resistance in EGFR-mutant adenocarcinoma upon treatment with TKIs, but rarely reported with programmed death1 (PD-1) inhibitors. We report two cases of potential transformation during treatment with PD-1 inhibitors.Case presentationsCase 1, a 65-year-old man was diagnosed with stage IVa lung adenocarcinoma on pleural fluid cytology. He received six cycles of carboplatin and pemetrexed, then maintained on pemetrexed. He had disease progression after nine cycles of pemetrexed and was switched to nivolumab. He progressed after five cycles of nivolumab. Core biopsy of the lung mass revealed SCLC. Case 2, a 68-year-old man was diagnosed with two primary NSCLCs and underwent resection. He had recurrence after several months and was treated with four cycles of carboplatin, paclitaxel, and pembrolizumab on clinical trial, with partial response. He was continued on pembrolizumab and had disease progression after 30 cycles. Biopsy of the new lesions showed SCLC.DiscussionHistologic transformation from NSCLC to SCLC can be explained by the presence of a common cell precursor. Proposed molecular mechanisms include loss of RB1, TP53 mutations, and MYC amplification. The distinction between transformation and mixed histology tumors is challenging, especially when pathologic material used for the initial diagnosis is limited. The possibility of a second metachronous primary lung cancer cannot be excluded in our cases.ConclusionHistologic transformation with PD-1 inhibitors could be under-recognized. Disease progression should prompt re-biopsy to uncover new histology and change in treatment. Future studies are needed to elucidate mechanisms and predictors of transformation.

show abstract

Section: Discussionmentioning

confidence: 77%

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Abdallah

Nagasaka

Abdulfatah

et al. 2018

LCTT

View full text Add to dashboard Cite

show abstract

“…The incidence of subsequent cancers among patients treated for lung cancer is estimated to range between 13.4% (Rosso, et al [33]) and 22% (Sanchez, et al [34]). The most common scenario is a diagnosis of another lung cancer with a different histological pattern.…”

Section: Discussionmentioning

confidence: 99%

“…According to Baskarl, et al [35], the histological results of the second tumor of the lung are as follows: adenomatous carcinoma (29.9% of all tumors), squamous cell carcinoma (27.1%), and small cell carcinoma (7.9%). The principal cause of multiple primary tumors of the lung is smoking; and radiotherapy does not have a major impact on the incidence of secondary lung cancer [34].…”

Section: Discussionmentioning

confidence: 99%

Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Epidemiological studies have reported the incidence of multiple primary lung cancers (MPLC) from 5.6% to 22% [1][2][3][4]. Genetic predisposition and environment exposure contribute to the development of MPLC [1].…”

Section: Introductionmentioning

confidence: 99%

Multiple primary synchronous tumors in the lungs

et al. 2021

View full text Add to dashboard Cite

Introduction. The aim of this manuscript was to report a case series of three patients diagnosed with multiple primary synchronous cancers (MPSC) in the lungs who were treated multidisciplinary at a single-center institution. Outline of cases. Three male patients were referred to the Clinic for Chest Surgery, at the Military Medical Academy in Belgrade, Serbia for planned surgical treatment of previously detected lung cancers. During subsequent diagnostic procedures, second primary synchronous tumors were detected in all presented cases. All patients underwent surgical resection and chemotherapy or a combination of chemo- and radio- therapy. Two of three patients died with an average survival period of 32 months. One patient is still alive, with current disease-free interval of 21 months. Conclusion. MPSC is a rare condition. The final diagnosis should be based on clinical, radiological, histopathological, and genetic analyses. Treatment modalities of MPSC depend on the clinical staging of the disease, patient?s general medical condition, and general assessment of tumor operability and resectability.

show abstract

Recidivas y segundos tumores en el cáncer de pulmón de larga supervivencia

Cited by 11 publications

References 21 publications

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries

Multiple primary synchronous tumors in the lungs

Contact Info

Product

Resources

About